October 11, 2016 – bioMérieux, a world leader in the field of in vitro diagnostics, announced that BioFire Diagnostics, LLC, its molecular biology affiliate, received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the FilmArray® Respiratory Panel EZ (RP EZ).
Due to the impact of Hurricane Matthew the southeast and mid-Atlantic delivery services by national carriers has been interrupted.
Foreign-Direct Investment Growing Global is the St. Louis region's premier event for the international business community.
Back-to-back events and symposia making National Sepsis Awareness Month 2016 the most eventful since Sepsis Month was launched 5 years ago!
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2016. The statements had been reviewed by the Statutory Auditors.
The new system demonstrates bioMérieux’s commitment to automated blood culture - a foundational step to infectious disease diagnosis
Marcy l'Etoile (France), July 18, 2016 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review for the six months ended June 30, 2016.
bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce the launch, on the occasion of the ASM Microbe 2016 (June 16-20, Boston), of its dedicated educational website on antimicrobial resistance.
In 2015, bioMérieux delivered a solid performance in terms of both sales and operating income, perfectly in line with the objectives we set for the business.
bioMérieux, a global player in in vitro diagnostics and world leader in industrial microbiological control, announces the acquisition of Hyglos, a Bernried (Germany) - based company specializing in the detection of endotoxins.
